ISRCTN12908359已完成未知
A double-blind, parallel, randomized, multicenter study to evaluate the safety and efficacy of NR034 (Ginuril®) versus lactic acid administered as co-adjuvant by vaginal route in women affected by a vaginal yeast infection and who are initiating treatment with clotrimazole vaginal tablets
ovintethical Pharma (Switzerland)0 个研究点目标入组 42 人开始时间: 2021年12月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Females between 18 and 50 years of age
- •2. Caucasian race
- •3. Suffering from vaginal yeast infection
- •4. Initiating therapy with clotrimazole vaginal tablets for 3 days
- •5. Signed informed consent form
排除标准
- •1. Pregnant women or breastfeeding
- •2. Unwilling to sign the informed consent form
- •3. Allergy to one of the product ingredients
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-FRovartis Pharma Services AG1,018
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-GRovartis Pharma Services AG1,018
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-DEovartis Pharma Services AG1,018
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-FIovartis Pharma Services AG1,018
进行中（未招募）
不适用
A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg aloneHypertensionEUCTR2006-004586-34-SEovartis Pharma Services AG1,018